AMLX compared with RLAY: revenue, margins and what each company keeps, and the suppliers and customers both name

AMLXAmylyx Pharmaceuticals, Inc.

Mkt capRevenueRevenue

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMLXAmylyx Pharmaceuticals, Inc.

RLAYRelay Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMLX 0

None

Shared 0

No disclosed counterparties: AMLX.

Only RLAY 3

—D.E. Shaw Researchunlistedsupplier

—Elevar Therapeuticsunlistedcustomer

—Genentechunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

AMLXAmylyx Pharmaceuticals, Inc.

28.86· pre 28.10

Mkt cap$3.2BRevenue$416,000Q3 FY24

RLAYRelay Therapeutics, Inc.

18.35· pre 18.84

Pre-marketSep 2 '83

Mkt cap$4.0BRevenue$350,000Q2 FY26

Compare

Pre-marketSep 2 '83

AMLXAmylyx Pharmaceuticals, Inc.

RLAYRelay Therapeutics, Inc.

28.86pre 28.10

Price

18.35pre 18.84

$3.2B

Mkt cap

$4.0B

Q3 FY24$416,000

Revenue

$350,000Q2 FY26

AMLX28.86vsRLAY18.35Pre-marketSep 2 '83